Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

The Company Intends to Request a Review of the Delisting Determination

CRANBURY, N.J., May 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC (“NYSE American”) stating that the NYSE Regulation has determined to commence proceedings to delist Palatin’s common stock. The notice, issued under Section 1003(f)(v) of the NYSE American Company Guide, cites the low selling price of Palatin’s common stock as the basis for delisting.

As a result, trading of Palatin’s common stock on the NYSE American has been immediately suspended, and the shares will transition to the OTC Pink Market under the ticker symbol “PTNT”…